Principia leads €10m series-A for CheckMab

With the fresh capital, CheckMab plans to move its research into the pre-clinical stage within the next three years. After achieving that result, the company intends to raise a second funding round that will enable its programme to reach a phase-I clinical trial.

Principia told Unquote that it was attracted to the high potential of the research developed by CheckMab and its new approach in the field of anti-cancer immunotherapy.

The VC house deployed capital from its healthcare-dedicated vehicle Principia III – Health to finance the investment. The fund was launched in 2014 and raised €206m, of which around €100m has so far been invested across 11 companies.

In July 2017, the GP launched its fifth fund, Utopia, with a €70m target and a focus on the life sciences sector.

Company
Founded as a spinout from Milan University La Statale and developed in partnership with Istituto Nazionale di Genetica Molecolare, CheckMab specialises in developing monoclonal antibodies able to stimulate the patient's immune system to attack tumour cells. The project was conceived by Milan University professors Sergio Abrignani and Massimiliano Pagani, who will direct the research programme in the coming years.

People
Principia – Antonio Falcone (CEO).
CheckMab – Sergio Abrignani, Massimiliano Pagani (professors, directors).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Venture
• Principia